Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary

Phillip J. Whiley, Lucia Guidugli, Logan C. Walker, Sue Healey, Bryony A. Thompson, Sunil R. Lakhani, Leonard M. Da Silva, Kconfab Investigators, Sean V. Tavtigian, David E. Goldgar, Melissa A. Brown, Fergus J Couch, Amanda B. Spurdle

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Clinical management of breast cancer families is complicated by identification of BRCA1 and BRCA2 sequence alterations of unknown significance. Molecular assays evaluating the effect of intronic variants on native splicing can help determine their clinical relevance. Twenty-six intronic BRCA1/2 variants ranging from the consensus dinucleotides in the splice acceptor or donor to 53 nucleotides into the intron were identified in multiple-case families. The effect of the variants on splicing was assessed using HSF matrices, MaxEntScan and NNsplice, followed by analysis of mRNA from lymphoblastoid cell lines. A total of 12 variants were associated with splicing aberrations predicted to result in production of truncated proteins, including a variant located 12 nucleotides into the intron. The posterior probability of pathogenicity was estimated using a multifactorial likelihood approach, and provided a pathogenic or likely pathogenic classification for seven of the 12 spliceogenic variants. The apparent disparity between experimental evidence and the multifactorial predictions is likely due to several factors, including a paucity of likelihood information and a nonspecific prior probability applied for intronic variants outside the consensus dinucleotides. Development of prior probabilities of pathogenicity incorporating bioinformatic prediction of splicing aberrations should improve identification of functionally relevant variants and enhance multifactorial likelihood analysis of intronic variants.

Original languageEnglish (US)
Pages (from-to)678-687
Number of pages10
JournalHuman Mutation
Volume32
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Introns
Exons
Nucleotides
Virulence
Computational Biology
Breast Neoplasms
Cell Line
Messenger RNA
Proteins

Keywords

  • BRCA1
  • BRCA2
  • Clinical significance
  • Variants

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. / Whiley, Phillip J.; Guidugli, Lucia; Walker, Logan C.; Healey, Sue; Thompson, Bryony A.; Lakhani, Sunil R.; Da Silva, Leonard M.; Investigators, Kconfab; Tavtigian, Sean V.; Goldgar, David E.; Brown, Melissa A.; Couch, Fergus J; Spurdle, Amanda B.

In: Human Mutation, Vol. 32, No. 6, 06.2011, p. 678-687.

Research output: Contribution to journalArticle

Whiley, PJ, Guidugli, L, Walker, LC, Healey, S, Thompson, BA, Lakhani, SR, Da Silva, LM, Investigators, K, Tavtigian, SV, Goldgar, DE, Brown, MA, Couch, FJ & Spurdle, AB 2011, 'Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary', Human Mutation, vol. 32, no. 6, pp. 678-687. https://doi.org/10.1002/humu.21495
Whiley, Phillip J. ; Guidugli, Lucia ; Walker, Logan C. ; Healey, Sue ; Thompson, Bryony A. ; Lakhani, Sunil R. ; Da Silva, Leonard M. ; Investigators, Kconfab ; Tavtigian, Sean V. ; Goldgar, David E. ; Brown, Melissa A. ; Couch, Fergus J ; Spurdle, Amanda B. / Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. In: Human Mutation. 2011 ; Vol. 32, No. 6. pp. 678-687.
@article{b728eececc5046268c933fceeeece53a,
title = "Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary",
abstract = "Clinical management of breast cancer families is complicated by identification of BRCA1 and BRCA2 sequence alterations of unknown significance. Molecular assays evaluating the effect of intronic variants on native splicing can help determine their clinical relevance. Twenty-six intronic BRCA1/2 variants ranging from the consensus dinucleotides in the splice acceptor or donor to 53 nucleotides into the intron were identified in multiple-case families. The effect of the variants on splicing was assessed using HSF matrices, MaxEntScan and NNsplice, followed by analysis of mRNA from lymphoblastoid cell lines. A total of 12 variants were associated with splicing aberrations predicted to result in production of truncated proteins, including a variant located 12 nucleotides into the intron. The posterior probability of pathogenicity was estimated using a multifactorial likelihood approach, and provided a pathogenic or likely pathogenic classification for seven of the 12 spliceogenic variants. The apparent disparity between experimental evidence and the multifactorial predictions is likely due to several factors, including a paucity of likelihood information and a nonspecific prior probability applied for intronic variants outside the consensus dinucleotides. Development of prior probabilities of pathogenicity incorporating bioinformatic prediction of splicing aberrations should improve identification of functionally relevant variants and enhance multifactorial likelihood analysis of intronic variants.",
keywords = "BRCA1, BRCA2, Clinical significance, Variants",
author = "Whiley, {Phillip J.} and Lucia Guidugli and Walker, {Logan C.} and Sue Healey and Thompson, {Bryony A.} and Lakhani, {Sunil R.} and {Da Silva}, {Leonard M.} and Kconfab Investigators and Tavtigian, {Sean V.} and Goldgar, {David E.} and Brown, {Melissa A.} and Couch, {Fergus J} and Spurdle, {Amanda B.}",
year = "2011",
month = "6",
doi = "10.1002/humu.21495",
language = "English (US)",
volume = "32",
pages = "678--687",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary

AU - Whiley, Phillip J.

AU - Guidugli, Lucia

AU - Walker, Logan C.

AU - Healey, Sue

AU - Thompson, Bryony A.

AU - Lakhani, Sunil R.

AU - Da Silva, Leonard M.

AU - Investigators, Kconfab

AU - Tavtigian, Sean V.

AU - Goldgar, David E.

AU - Brown, Melissa A.

AU - Couch, Fergus J

AU - Spurdle, Amanda B.

PY - 2011/6

Y1 - 2011/6

N2 - Clinical management of breast cancer families is complicated by identification of BRCA1 and BRCA2 sequence alterations of unknown significance. Molecular assays evaluating the effect of intronic variants on native splicing can help determine their clinical relevance. Twenty-six intronic BRCA1/2 variants ranging from the consensus dinucleotides in the splice acceptor or donor to 53 nucleotides into the intron were identified in multiple-case families. The effect of the variants on splicing was assessed using HSF matrices, MaxEntScan and NNsplice, followed by analysis of mRNA from lymphoblastoid cell lines. A total of 12 variants were associated with splicing aberrations predicted to result in production of truncated proteins, including a variant located 12 nucleotides into the intron. The posterior probability of pathogenicity was estimated using a multifactorial likelihood approach, and provided a pathogenic or likely pathogenic classification for seven of the 12 spliceogenic variants. The apparent disparity between experimental evidence and the multifactorial predictions is likely due to several factors, including a paucity of likelihood information and a nonspecific prior probability applied for intronic variants outside the consensus dinucleotides. Development of prior probabilities of pathogenicity incorporating bioinformatic prediction of splicing aberrations should improve identification of functionally relevant variants and enhance multifactorial likelihood analysis of intronic variants.

AB - Clinical management of breast cancer families is complicated by identification of BRCA1 and BRCA2 sequence alterations of unknown significance. Molecular assays evaluating the effect of intronic variants on native splicing can help determine their clinical relevance. Twenty-six intronic BRCA1/2 variants ranging from the consensus dinucleotides in the splice acceptor or donor to 53 nucleotides into the intron were identified in multiple-case families. The effect of the variants on splicing was assessed using HSF matrices, MaxEntScan and NNsplice, followed by analysis of mRNA from lymphoblastoid cell lines. A total of 12 variants were associated with splicing aberrations predicted to result in production of truncated proteins, including a variant located 12 nucleotides into the intron. The posterior probability of pathogenicity was estimated using a multifactorial likelihood approach, and provided a pathogenic or likely pathogenic classification for seven of the 12 spliceogenic variants. The apparent disparity between experimental evidence and the multifactorial predictions is likely due to several factors, including a paucity of likelihood information and a nonspecific prior probability applied for intronic variants outside the consensus dinucleotides. Development of prior probabilities of pathogenicity incorporating bioinformatic prediction of splicing aberrations should improve identification of functionally relevant variants and enhance multifactorial likelihood analysis of intronic variants.

KW - BRCA1

KW - BRCA2

KW - Clinical significance

KW - Variants

UR - http://www.scopus.com/inward/record.url?scp=79957603664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957603664&partnerID=8YFLogxK

U2 - 10.1002/humu.21495

DO - 10.1002/humu.21495

M3 - Article

VL - 32

SP - 678

EP - 687

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 6

ER -